echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Ilixadencel treatment of kidney cancer, the patient's survival period can be significantly prolonged

    Ilixadencel treatment of kidney cancer, the patient's survival period can be significantly prolonged

    • Last Update: 2021-03-19
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Biopharmaceutical company Immunicum today announced that in the updated data of the phase II MERECA randomized trial, ilixadencel combined with sunitinib has achieved positive results in the first-line treatment of patients with metastatic renal cell carcinoma (mRCC).


    Sunitinib

    As of February 2021, the separation of the Kaplan-Meier survival curve is conducive to the combination of ilixadencel.


    The proportion of surviving patients in the ilixadencel combination treatment group was 41% (23 out of 56 survived), compared to 30% in the control group (9 out of 30 survived).


     

    Original source:

    Original source:

    https://target="_blank" rel="noopener">https:// style="vertical-align: inherit;"> https:// leave a message here

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.